Loading…
← CockpitCompetitor Analysis › 600420.SS Shanghai Shyndec Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Shanghai Shyndec Pharmaceutical Co., Ltd. Class A600420.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Shanghai generics and traditional-medicine maker within the Fosun Pharma group, selling respiratory and other hospital drugs.

≈ A small Fosun-affiliated generics makerMomentum strong 75
Mkt cap
$1.59B
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$7.92M
20-day average traded
Fwd P/E
12.6×
forward earnings
ROIC−WACC
+0.1 pp
WACC 5.2%
Hurdle
-1 pp
Req g minus delivered
Next earnings
131 days
29 Mar 2027
Close · CNYCN¥7.92
1D-1.1%
1W-2.8%
1M-3.9%
3M-9.2%
6M-14.5%
YTD-21.6%
1Y-23.6%
ATR %1.8%
52w lowhigh28.6% off high

What Shanghai Shyndec Pharmaceutical does

Shanghai generics and traditional-medicine maker within the Fosun Pharma group, selling respiratory and other hospital drugs.

In one line: A small Fosun-affiliated generics maker.

Products and services

  • Respiratory generics
  • Traditional Chinese medicine products
  • Other hospital generics

Customers

  • Hospitals
  • Retail pharmacies

Where it sits in the supply chain

  • Pharmaceuticals
  • Generics and TCM
  • Hospital and OTC drugs

What could go right

  • Fosun group distribution support
  • New generic approvals

What could go wrong

  • Procurement tender price cuts

Moat: none (distribution). Commodity generics maker without a distinctive patented product line.

Headquarters: Shanghai, China · Employees: 9,697

Named competitors

Shanghai Shyndec Pharmaceutical at a glance

Size Shanghai Shyndec Pharmaceutical (600420.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.59B, the 1435th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.92 on 18 Nov 2026.

Performance Over six months the shares fell 14.5%, against -7.7% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 20 in its peer set.

Growth Revenue fell 13.1% over the last twelve months (peer median +6.8%); the operating margin is 6.2% (peer median 12.4%).

Valuation It trades at 12.6× forward earnings against a peer median of 26.0× (2nd cheapest of 15).

Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.1 points above its cost of capital (5.2% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

85909510021 May 202621 Aug 202618 Nov 2026Peer median 92600420.SS 87
Six months, rebased to 100: Shanghai Shyndec Pharmaceutical against the median of its 20 peers (local-currency closes).

Shanghai Shyndec Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥8.03BCN¥9.30BCN¥10.9BCN¥12.0BCN¥12.9B
Revenue growth—-14%-9%-7%—
Gross profitCN¥2.81BCN¥2.83BCN¥4.05BCN¥4.36BCN¥4.67B
EBITDAn/aCN¥1.82BCN¥2.30BCN¥1.78BCN¥1.69B
Net incomeCN¥451MCN¥942MCN¥1.08BCN¥692MCN¥628M
Free cash flowCN¥514MCN¥1.47BCN¥2.05BCN¥1.39BCN¥2.55B
Capital expenditureCN¥201MCN¥264MCN¥220MCN¥357MCN¥307M
Total debtCN¥1.33BCN¥1.19BCN¥1.69BCN¥1.75BCN¥3.86B

Quarterly statements and history in the cockpit →

Shanghai Shyndec Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-75%-50%-25%0%+25%-20%0%+20%JUBLPHARMA002755002675301047ANURAS002019ASTRAZEN000766SRPT1681600572300357603235298380INDGN600993CAPLIPOINT300723FAE600420.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai Shyndec Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×60×JUBLPHARMA002755002675301047ANURAS0020191681600572300357INDGN600993CAPLIPOINT300723FAE600420.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai Shyndec Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%002755002675301047ASTRAZEN000766SRPT1681600572300357603235INDGN600993CAPLIPOINT300723FAE600420.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shanghai Shyndec Pharmaceutical is the large dot.

Shanghai Shyndec Pharmaceutical competitors and peer comparison

Head to head with its named competitors (600420.SS vs 600196.SS vs 000999.SZ vs 000538.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shanghai Shyndec Pharmaceutical 600420.SS$1.59B-14%-13%6%12.6×-6.6%
Shanghai Fosun Pharmaceutical (Group) 600196.SS$7.57B-14%+8%6%14.8×2.9%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZ$6.59B+6%+4%14%13.2×-6.2%
Yunnan Baiyao 000538.SZ$15.0B+11%+5%11%18.3×-0.2%

How Shanghai Shyndec Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai Shyndec Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600420.SSPeer medianRank in peer set
1-month return-3.9%-4.5%11th highest of 21
6-month return-14.5%-7.7%8th lowest of 20
Distance from 52-week high-28.6%-33.2%10th highest of 21
Revenue growth (TTM)-13.1%+6.8%5th lowest of 20
Operating margin6.2%12.4%4th lowest of 20
Forward P/E12.6×26.0×2nd cheapest of 15
Growth the price implies (Req g, 7 yrs)-6.6%11.3%3rd least demanding of 16
Growth delivered (Del g)-5.6%+6.8%4th lowest of 16
Hurdle (Req g minus delivered)-1.0 pp+7.6 pp7th least demanding of 16
ROIC minus cost of capital+0.1 pp+1.2 pp10th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shanghai Shyndec Pharmaceutical 600420.SSChina$1.59B-14%-13%6%12.6×-6.6%-5.6%
Jubilant Pharmova JUBLPHARMA.NSIndia$1.59B-8%+18%7%29.0×n/an/a
Beijing Aosaikang Pharmaceutical 002755.SZChina$1.60B-31%-13%12%57.4×12.8%-14.0%
Yantai Dongcheng Biochemicals 002675.SZChina$1.59B0%-4%15%47.2×6.0%-4.3%
Sino Biological 301047.SZChina$1.60B+27%+20%17%51.6×31.1%-15.1%
Anupam Rasayan India ANURAS.NSIndia$1.61B-3%+24%16%49.9×n/an/a
Yifan Pharmaceutical 002019.SZChina$1.57B-19%-5%8%25.6×n/an/a
AstraZeneca Pharma India ASTRAZEN.NSIndia$1.62B-30%+30%10%n/a42.4%+23.0%
Tonghua Golden-Horse Pharmaceutical Industry 000766.SZChina$1.62B-47%-18%9%n/a33.0%+0.9%
Sarepta Therapeutics SRPTUnited States$1.56B-15%-19%0%n/a-6.8%+32.4%
Consun Pharmaceutical 1681.HKHong Kong$1.65B+8%+15%35%9.2×-14.9%+13.5%
Zhejiang CONBA Pharmaceutical 600572.SSChina$1.52B-4%+4%9%16.0×-6.1%+1.9%
Braveheart Bio BRVEUnited States$1.67Bn/an/an/an/an/an/a
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZChina$1.67B-12%+7%39%26.3×18.4%+10.8%
JiangXi Tianxin Pharmaceutical 603235.SSChina$1.52B-9%+16%24%n/a-4.9%+0.2%
ABL Bio 298380.KSSouth Korea$1.51B-71%-53%-201%n/an/an/a
Indegene INDGN.NSIndia$1.69B+28%+36%12%29.5×31.4%+29.4%
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%17.0×-3.5%+6.8%
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%21.4×24.3%+15.7%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%22.0×11.3%-11.0%
Faes Farma FAE.MCSpain$1.71B+6%+32%14%17.4×3.7%+9.9%

Questions

Who are Shanghai Shyndec Pharmaceutical's main competitors?
Named competitors: Fosun Pharma (600196.SS), China Resources Sanjiu (000999.SZ), Yunnan Baiyao (000538.SZ). The cockpit's measured peer set (industry) also includes Jubilant Pharmova (JUBLPHARMA.NS), Beijing Aosaikang Pharmaceutical (002755.SZ), Yantai Dongcheng Biochemicals (002675.SZ), Sino Biological (301047.SZ), Anupam Rasayan India (ANURAS.NS), Yifan Pharmaceutical (002019.SZ).
Is Shanghai Shyndec Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 12.6× against a peer median of 26.0×, 2nd cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has Shanghai Shyndec Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -14.5% against -7.7% for the median peer; over one year -23.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.